Citadel Advisors
LUCD icon

Citadel Advisors’s Lucid Diagnostics LUCD Stock Holding History

Citadel Advisors’s Portfolio LUCD Stock Details LUCD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$38.9K Buy
+36,362
New +$39.2K ﹤0.01% 13235
2026
Q1 		– Sell
-56,210
Closed -$61.3K – 13691
2025
Q4 		$61.3K Buy
+56,210
New +$62.8K ﹤0.01% 11936
2025
Q2 		– Sell
-121,430
Closed -$181K – 13988
2025
Q1 		$181K Buy
121,430
+1,543
+1% +$1.85K ﹤0.01% 10591
2024
Q4 		$98.2K Buy
+119,887
New +$106K ﹤0.01% 11511
2024
Q2 		– Sell
-29,301
Closed -$23.7K – 14947
2024
Q1 		$23.7K Sell
29,301
-338
-1% -$439 ﹤0.01% 12886
2023
Q4 		$41.8K Sell
29,639
-6,736
-19% -$8.88K ﹤0.01% 11973
2023
Q3 		$42.6K Sell
36,375
-26,136
-42% -$37.9K ﹤0.01% 11938
2023
Q2 		$86.9K Buy
+62,511
New +$94.2K ﹤0.01% 11137
2022
Q4 		– Sell
-35,333
Closed -$54K – 15217
2022
Q3 		$54K Buy
35,333
+4,506
+15% +$11.2K ﹤0.01% 11570
2022
Q2 		$70K Buy
30,827
+10,332
+50% +$23K ﹤0.01% 11708
2022
Q1 		$69K Buy
+20,495
New +$74.9K ﹤0.01% 12588

Other funds holding LUCD

Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
MCM
Masters Capital Management Atlanta, Georgia $3.9B AUM 50.88% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
First Manhattan
First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Citadel Advisors's LUCD Position: Q2 2026 in Review

Citadel Advisors opened a new position in Lucid Diagnostics (LUCD) in Q2 2026: 36,362 shares worth $38.9K. The stake represents ﹤0.01% of the portfolio and ranks #13235 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in LUCD as recently as Q4 2025.

Citadel Advisors first reported a position in LUCD in Q1 2022 and has held it in 11 quarters since. The position peaked at $181K in Q1 2025. 116 funds tracked by Wall St. Rank hold LUCD as of Q2 2026.

  • Citadel Advisors held 36,362 shares of Lucid Diagnostics worth $38.9K as of Q2 2026.
  • Lucid Diagnostics was a new Citadel Advisors position in Q2 2026.
  • Lucid Diagnostics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #13235 holding.
  • Citadel Advisors first reported a position in Lucid Diagnostics in Q1 2022 and has held it in 11 quarters since.
  • Citadel Advisors's Lucid Diagnostics position peaked at $181K in Q1 2025.
  • 116 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.